|
1
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
3
|
Malthaner RA, Wong RK, Rumble RB and Zuraw
L: Neoadjuvant or adjuvant therapy for resectable esophageal
cancer: a systematic review and meta-analysis. BMC Med. 2:352004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gebski V, Burmeister B, Smithers BM, Foo
K, Zalcberg J and Simes J: Survival benefits from neoadjuvant
chemoradiotherapy or chemotherapy in oesophageal carcinoma: a
meta-analysis. Lancet Oncol. 8:226–234. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tepper J, Krasna MJ, Niedzwiecki D, et al:
Phase III trial of trimodality therapy with cisplatin,
fluorouracil, radiotherapy, and surgery compared with surgery alone
for esophageal cancer: CALGB 9781. J Clin Oncol. 26:1086–1092.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shinohara M, Ohyama N, Murata Y, et al:
CD47 regulation of epithelial cell spreading and migration, and its
signal transduction. Cancer Sci. 97:889–895. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Oldenborg PA, Zheleznyak A, Fang YF,
Lagenaur CF, Gresham HD and Lindberg FP: Role of CD47 as a marker
of self on red blood cells. Science. 288:2051–2054. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Okazawa H, Motegi S, Ohyama N, et al:
Negative regulation of phagocytosis in macrophages by the
CD47-SHPS-1 system. J Immunol. 174:2004–2011. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
van den Berg TK and van der Schoot CE:
Innate immune ‘self’ recognition: a role for CD47-SIRPalpha
interactions in hematopoietic stem cell transplantation. Trends
Immunol. 29:203–206. 2008.
|
|
10
|
Oldenborg PA, Gresham HD, Chen Y, Izui S
and Lindberg FP: Lethal autoimmune hemolytic anemia in
CD47-deficient nonobese diabetic (NOD) mice. Blood. 99:3500–3504.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jaiswal S, Chao MP, Majeti R and Weissman
IL: Macrophages as mediators of tumor immunosurveillance. Trends
Immunol. 31:212–219. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Majeti R, Chao MP, Alizadeh AA, et al:
CD47 is an adverse prognostic factor and therapeutic antibody
target on human acute myeloid leukemia stem cells. Cell.
138:286–299. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chao MP, Alizadeh AA, Tang C, et al:
Therapeutic antibody targeting of CD47 eliminates human acute
lymphoblastic leukemia. Cancer Res. 71:1374–1384. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nagahara M, Mimori K, Kataoka A, et al:
Correlated expression of CD47 and SIRPA in bone marrow and in
peripheral blood predicts recurrence in breast cancer patients.
Clin Cancer Res. 16:4625–4635. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Junker A, Krumbholz M, Eisele S, et al:
MicroRNA profiling of multiple sclerosis lesions identifies
modulators of the regulatory protein CD47. Brain. 132:3342–3352.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Valencia-Sanchez MA, Liu J, Hannon GJ and
Parker R: Control of translation and mRNA degradation by miRNAs and
siRNAs. Genes Dev. 20:515–524. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lu J, Getz G, Miska EA, et al: MicroRNA
expression profiles classify human cancers. Nature. 435:834–838.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Volinia S, Calin GA, Liu CG, et al: A
microRNA expression signature of human solid tumors defines cancer
gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guo Y, Chen Z, Zhang L, et al: Distinctive
microRNA profiles relating to patient survival in esophageal
squamous cell carcinoma. Cancer Res. 68:26–33. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Childs G, Fazzari M, Kung G, et al:
Low-level expression of microRNAs let-7d and miR-205 are prognostic
markers of head and neck squamous cell carcinoma. Am J Pathol.
174:736–745. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP
and Wei WI: Mature miR-184 as potential oncogenic microRNA of
squamous cell carcinoma of tongue. Clin Cancer Res. 14:2588–2592.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nohata N, Hanazawa T, Kikkawa N, et al:
Caveolin-1 mediates tumor cell migration and invasion and its
regulation by miR-133a in head and neck squamous cell carcinoma.
Int J Oncol. 38:209–217. 2011.PubMed/NCBI
|
|
25
|
Chiyomaru T, Enokida H, Tatarano S, et al:
miR-145 and miR-133a function as tumour suppressors and directly
regulate FSCN1 expression in bladder cancer. Br J Cancer.
102:883–891. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Song T, Xia W, Shao N, et al: Differential
miRNA expression profiles in bladder urothelial carcinomas. Asian
Pac J Cancer Prev. 11:905–911. 2010.PubMed/NCBI
|
|
27
|
Bandres E, Cubedo E, Agirre X, et al:
Identification by real-time PCR of 13 mature microRNAs
differentially expressed in colorectal cancer and non-tumoral
tissues. Mol Cancer. 5:292006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Missiaglia E, Shepherd CJ, Patel S, et al:
MicroRNA-206 expression levels correlate with clinical behaviour of
rhabdomyosarcomas. Br J Cancer. 102:1769–1777. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rao PK, Missiaglia E, Shields L, et al:
Distinct roles for miR-1 and miR-133a in the proliferation and
differentiation of rhabdomyosarcoma cells. FASEB J. 24:3427–3437.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kano M, Seki N, Kikkawa N, et al: miR-145,
miR-133a and miR-133b: Tumor suppressive miRNAs target FSCN1 in
esophageal squamous cell carcinoma. Int J Cancer. 127:2804–2814.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hashimoto Y, Ito T, Inoue H, et al:
Prognostic significance of fascin overexpression in human
esophageal squamous cell carcinoma. Clin Cancer Res. 11:2597–2605.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang H, Madariaga ML, Wang S, Van Rooijen
N, Oldenborg PA and Yang YG: Lack of CD47 on non-hematopoietic
cells induces split macrophage tolerance to CD47null cells. Proc
Natl Acad Sci USA. 104:13744–13749. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kuwano H, Nakajima M, Miyazaki T and Kato
H: Distinctive clinicopathological characteristics in esophageal
squamous cell carcinoma. Ann Thorac Cardiovasc Surg. 9:6–13.
2003.PubMed/NCBI
|
|
35
|
Nagata H, Arai T, Soejima Y, Suzuki H,
Ishii H and Hibi T: Limited capability of regional lymph nodes to
eradicate metastatic cancer cells. Cancer Res. 64:8239–8248. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Asano K, Nabeyama A, Miyake Y, et al:
CD169-positive macrophages dominate antitumor immunity by
crosspresenting dead cell-associated antigens. Immunity. 34:85–95.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Soifer HS, Rossi JJ and Saetrom P:
MicroRNAs in disease and potential therapeutic applications. Mol
Ther. 15:2070–2079. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Elmen J, Lindow M, Schutz S, Lawrence M,
et al: LNA-mediated microRNA silencing in non-human primates.
Nature. 452:896–899. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Silvestri P, Di Russo C, Rigattieri S, et
al: MicroRNAs and ischemic heart disease: towards a better
comprehension of pathogenesis, new diagnostic tools and new
therapeutic targets. Recent Pat Cardiovasc Drug Discov. 4:109–118.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chan KS, Espinosa I, Chao M, et al:
Identification, molecular characterization, clinical prognosis, and
therapeutic targeting of human bladder tumor-initiating cells. Proc
Natl Acad Sci USA. 106:14016–14021. 2009. View Article : Google Scholar
|
|
41
|
Chao MP, Alizadeh AA, Tang C, et al:
Anti-CD47 antibody synergizes with rituximab to promote
phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 142:699–713.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chao MP, Alizadeh AA, Tang C, et al:
Therapeutic antibody targeting of CD47 eliminates human acute
lymphoblastic leukemia. Cancer Res. 71:1374–1384. 2010. View Article : Google Scholar : PubMed/NCBI
|
